The knockdown of CD44v6 in prostate cancer cell lines has been demonstrated to enhance chemo/radiosensitivity, with the underlying mechanism involving the downregulation of the PI3K/AKT/mTOR and Wnt/β-catenin signalling pathways [17]. This evidence concerns the gene MTOR and prostate cancer.